Statistics of Productivity and Effectiveness of Experimental Support of the Educational System (For Scientists and Education Experts)

The present article focuses on the issues of productivity and effectiveness of research providing educational system. This work describes research activity as an activity of the authors- individuals and groups of the authors, and also an activity of scientific and educational institutions which are carrying out their activity within the education system in the field of development, registration, approbation and implementation of teaching and education techniques and technologies, new mechanisms of management in the education system, control of the quality of education and also in other directions provided by the programs of education development and other normative legal acts defining priorities of the state education policy of the Russian Federation. The article has considered the dynamics of a branch registration of the results of intellectual activity (RIA) in the field of education in recent years. It has also given the statistics of scientific providing education system on materials of a database and information collections of the Joint fund of Electronic Resources "Science and education" (JFERSaE). The examples of integrating collections of electronic resources developed by the JFERSaE experts have been considered. The systematized review of specifics of the technology of a branch registration of electronic resources is a distinctive feature of the work. Now an actual problem for many authors creating various objects of the intellectual property for the education system is a legal protection of their rights. The legislator for computer programs says, many types of works existing only in the electronic form do not provide for a special registration, databases, etc. A the same time, the authors- workers of educational institutions in the course of implementation of the labor functions often face a need of the authors’ rights confirmation for their electronic works included in electronic educational systems and forming in turn information and education space of a country. DOI: 10.5901/mjss.2015.v6n5s3p6

Efficacy of Pneumococcal Polysaccharide Conjugate Vaccine (13-valent, Adsorbed) in Patients with Systemic Juvenile Idiopathic Arthritis Treated with Genetically Engineered Biologic Drugs (Tocilizumab or Canakinumab): Prospective Cohort Study

Background. Immunological potency of 13-valent pneumococcal vaccine (PCV-13) in children with systemic juvenile idiopathic arthritis (SJIA) is still unstudied. Estimates of the genetically engineered biologic drugs (GEBD) effects on pneumococcal vaccination results also remain controversial.Objective. The aim of the study was to explore the PCV-13 efficacy in patients with SJIA and who is on treatment with monoclonal antibodies against interleukin 6 receptor (tocilizumab) and interleukin 8 receptor beta (canakinumab).Methods. The study included patients under the age of 18 with SJIA in remission or active form of disease vaccinated with PCV-13. The vaccine was administered in single dose of 0.5 ml intramuscularly in patients on treatment with GEBD or 3 weeks before GEBD administration for the first time (for patients with active disease). Vaccination was considered effective at achievement of the minimum protective level of antibodies to capsular polysaccharide of pneumococcus (anti-SPP IgG; ≥ 7 U/ml) or increase of anti-SPP IgG level ≥ 2 times in 4 weeks after vaccination. The anti-SPP IgG levels were measured with enzyme immunoassay.Results. The study included 53 patients (27 girls) in remission of SJIA and 25 (16 girls) in active disease. Median age was 13.3 and 10.8 years respectively. Tocilizumab/canakinumab was administrated in 43/10 and 18/7 patients respectively. Minimum significant anti-SPP IgG level and two-fold increase in anti-SPP IgG level were recorded in 49/53 (92%) and 32/53 (60%) patients with SJIA in remission, as well as in 22/25 (88%) and 18/25 (72%) patients in active disease respectively. PCV-13 immunological potency in patients with SJIA in remission and in active disease (in those who were initially administrated and who did not receive GEBD) did not differ.Conclusion. PCV-13 vaccination allows to achieve protective antibodies level in most of the patients with SJIA in children population regardless of the disease stage and the history of GEBD administration

Stress neuropeptide levels in adults with chest pain due to coronary artery disease: potential implications for clinical assessment

: Substance P (SP) and neuropeptide Y (NPY) are neuropeptides involved in nociception. The study of biochemical markers of pain in communicating critically ill coronary patients may provide insight for pain assessment and management in critical care. Purpose of the study was to to explore potential associations between plasma neuropeptide levels and reported pain intensity in coronary critical care adults, in order to test the reliability of SP measurements for objective pain assessment in critical care